TCRX TScan Therapeutics, Inc.: רווח למניה לשנה מתגלגלת

This chart of the current market value of TScan Therapeutics (TCRX) demonstrates the 21.10 indicator. TScan Therapeutics (TCRX) strictly adheres to bio-waste disposal regulations. The business relies on the development of T-cell tumor treatments, although a lack of sales and R&D expenses hinder profit growth. The project's success is based on the precision of target identification within cells and market confidence in the results of primary safety tests.

This indicator measures the trailing twelve-month (TTM) net income per share, neutralizing time gaps between quarterly reports to assess earnings growth rates. By analyzing the year-over-year change in EPS (TTM), an investor can evaluate the sustainability of the TScan Therapeutics (TCRX) business model, where massive R&D expenditures and the patent protection of the Barriers platform determine the asset's long-term fundamental value.